Johnson & Johnson $JNJ Position Lessened by Brookstone Capital Management

Brookstone Capital Management decreased its position in Johnson & Johnson (NYSE:JNJ) by 5.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 71,225 shares of the company’s stock after selling 4,203 shares during the period. Brookstone Capital Management’s holdings in Johnson & Johnson were worth $13,207,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Triangle Securities Wealth Management grew its holdings in Johnson & Johnson by 9.1% in the 3rd quarter. Triangle Securities Wealth Management now owns 19,360 shares of the company’s stock worth $3,590,000 after buying an additional 1,611 shares in the last quarter. Symmetry Partners LLC boosted its position in Johnson & Johnson by 12.3% during the 3rd quarter. Symmetry Partners LLC now owns 7,273 shares of the company’s stock worth $1,348,000 after acquiring an additional 797 shares during the period. Global X Japan Co. Ltd. grew its stake in shares of Johnson & Johnson by 384.4% in the third quarter. Global X Japan Co. Ltd. now owns 19,789 shares of the company’s stock worth $3,669,000 after purchasing an additional 15,704 shares in the last quarter. Swedbank AB increased its holdings in shares of Johnson & Johnson by 8.4% during the third quarter. Swedbank AB now owns 2,177,506 shares of the company’s stock valued at $403,753,000 after purchasing an additional 168,857 shares during the period. Finally, BayBridge Capital Group LLC bought a new stake in shares of Johnson & Johnson during the third quarter valued at about $1,150,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.1%

JNJ stock opened at $207.54 on Friday. The company has a 50 day moving average of $199.67 and a two-hundred day moving average of $180.86. The company has a market cap of $500.02 billion, a price-to-earnings ratio of 20.03, a PEG ratio of 2.25 and a beta of 0.36. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $215.18. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion during the quarter. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.5%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on JNJ shares. Daiwa Capital Markets raised Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price on the stock in a report on Monday, October 20th. Bank of America boosted their price objective on Johnson & Johnson from $204.00 to $220.00 and gave the stock a “neutral” rating in a research note on Monday, December 15th. Loop Capital set a $190.00 target price on Johnson & Johnson in a research note on Wednesday, October 22nd. Royal Bank Of Canada set a $240.00 target price on Johnson & Johnson in a report on Wednesday, December 17th. Finally, The Goldman Sachs Group upped their price target on shares of Johnson & Johnson from $213.00 to $240.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Four analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $210.25.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.